• Q1 revenue growth: Revenue grew 19.1% in Q1—the highest in four years—driven by the addition of around 32 labs, over 2,000 collection centers in tier 3 and 4 cities, and the launch of more than 100 new tests.
• Pan-India demand: Traction was broad-based across all regions and segments, supported by sustained momentum in the Swasthfit wellness portfolio and high-end test demand from the Medilumina event.
• Full-year guidance: Management remains confident in achieving mid-teens revenue growth for the full year, though a more specific annual forecast will be shared after Q2 results.
• Inorganic growth strategy: The company is actively evaluating acquisition opportunities using cash on its balance sheet, with a primary focus on acquiring scalable assets in South and West India.